Poolbeg Pharma PLC (POLB.L)
GBp 7.18
(-2.31%)
GBp 7.18
(-2.31%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Operating Cash Flow | -3.84 Million | -4.36 Million | -2.14 Million |
| Net Income | -3.93 Million | -4.77 Million | -2.33 Million |
| Depreciation & Amortization | 26 Thousand | 26 Thousand | 18 Thousand |
| Deferred income taxes | - | 91 Thousand | -782 Thousand |
| Stock-based compensation | 50 Thousand | 429 Thousand | 240 Thousand |
| Change in working capital | 229 Thousand | 72 Thousand | -68 Thousand |
| Other non-cash items | -354 Thousand | -209 Thousand | 782 Thousand |
| Investing Cash Flow | -175 Thousand | -388 Thousand | -81 Thousand |
| Investments in PPE | -175 Thousand | -597 Thousand | -81 Thousand |
| Acquisitions | - | - | - |
| Investment purchases | - | - | - |
| Sales/Maturities of investments | - | - | - |
| Other Investing Activities | 359.00 | 209 Thousand | -108.00 |
| Financing Cash Flow | - | - | 23.17 Million |
| Debt repayment | - | - | -225 Thousand |
| Dividends payments | - | - | - |
| Common Stock Repurchased | - | - | - |
| Common Stock Issuance | - | - | 23.17 Million |
| Other Financing Activities | - | - | 225 Thousand |
| Accounts receivables | 209 Thousand | -456 Thousand | -506 Thousand |
| Accounts payables | - | - | - |
| Inventory | - | - | - |
| Other working capital | 20 Thousand | 528 Thousand | 438 Thousand |
| Cash at beginning of period | 16.19 Million | 20.94 Million | - |
| Cash at end of period | 12.17 Million | 16.19 Million | 20.94 Million |
| Capital Expenditure | -175 Thousand | -597 Thousand | -81 Thousand |
| Effect of forex changes on cash | - | - | - |
| Net cash flow / Change in cash | -4.02 Million | -4.75 Million | 20.94 Million |
| Free Cash Flow | -4.02 Million | -4.96 Million | -2.22 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -1129.00 | -1129.00 | -3.93 Million | -1060.00 | -1060.00 | -1.81 Million |
| Depreciation & Amortization | 6.50 | 6.50 | 26 Thousand | 6.50 | 6.50 | 13 Thousand |
| Deferred income taxes | - | - | - | - | - | 168.97 Thousand |
| Stock-based compensation | 132.50 | 132.50 | 50 Thousand | 1.50 | 1.50 | 23.50 |
| Change in working capital | -5.00 | -5.00 | 229 Thousand | 7.00 | 7.00 | -260 Thousand |
| Other non-cash items | -136.00 | -136.00 | -354 Thousand | -4.00 | -4.00 | -122 Thousand |
| Investing Cash Flow | 76.00 | 76.00 | -175 Thousand | 74.50 | 74.50 | -62 Thousand |
| Investments in PPE | - | - | -175 Thousand | -113 Thousand | - | -62 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 76.00 | 76.00 | 359.00 | 74.50 | 74.50 | 105.00 |
| Financing Cash Flow | - | - | - | - | - | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | - | - | - | - |
| Accounts receivables | -5.00 | -5.00 | 209 Thousand | 7.00 | 7.00 | 195 Thousand |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | 20 Thousand | 475 Thousand | - | -455 Thousand |
| Cash at beginning of period | - | - | 16.19 Million | 14.12 Million | - | 16.19 Million |
| Cash at end of period | -1055.00 | -1055.00 | 12.17 Million | 12.17 Million | -974.50 | 14.12 Million |
| Capital Expenditure | - | - | -175 Thousand | -113 Thousand | - | -62 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -1055.00 | -1055.00 | -4.02 Million | -1.94 Million | -974.50 | -2.07 Million |
| Free Cash Flow | -1131.00 | -1131.00 | -4.02 Million | -114.04 Thousand | -1049.00 | -2.07 Million |
API
FREKF
001270
HUI
MAPS
000565